Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

Nutrition, metabolism, and cardiovascular diseases : NMCD

Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.

Nutrition, metabolism, and cardiovascular diseases : NMCD

Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?

Nutrition, metabolism, and cardiovascular diseases : NMCD

Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.

JAMA health forum

Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - is it time to reconsider clinical practice?

Expert review of clinical pharmacology

Peripheral artery disease: advances in medical therapy.

European heart journal

Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.

Frontiers in endocrinology

Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.

European journal of case reports in internal medicine

The most popular peptides in the research and biohacking world right now: → BPC-157 (healing) → TB-500 (recovery) → Retatrutide (fat loss) → Semaglutide & Tirzepatide (fat loss) → CJC-1295 + Ipamorelin (growth hormone) → Semax & Selank (focus)

i've been open about my personal journey with peptides and building at the forefront of longevity. at zelta we've helped over 570+ patients lose weight with GLP-1, while semaglutide is FDA-approved with clear regulation and data behind it, the wider peptide space runs on louder https://t.co/uI7ckgtmOp

In 8 days the FDA decides the fate of the peptides half of biohacking Twitter is already taking. On July 23–24 it reviews seven of them: In 8 days the FDA decides the fate of the peptides half of biohacking Twitter is already taking. On July 23–24 it reviews seven of them: https://t.co/RGzXfWqBBx

THE FDA STACKED ITS PEPTIDE PANEL WITH PEOPLE WHO SELL PEPTIDES. On July 23-24, an FDA advisory committee votes on whether to recommend BPC-157, TB-500 and 5 other peptides for a legal compounding pathway. Per the AP, the panel now includes more than a half-dozen members with

🕵️With PCOS (polycystic ovary syndrome) being reclassified as PMOS (polyendocrine metabolic syndrome), thought I’d review the current PCOS and infertility related trials currently recruiting. (Also, a friend was asking!) Many women report meaningful improvements with PCOS

Every research category. One source. METABOLIC Retatrutide · Semaglutide · Tirzepatide GROWTH HORMONE HGH · CJC-1295 · Ipamorelin · Tesamorelin RECOVERY BPC-157 · TB-500 · KPV · ARA-290 WELLNESS & LONGEVITY NAD+ · GHK-Cu · Epithalon · MOTS-C NOOTROPICS Semax · Selank All

Next week, July 23-24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides being considered for inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon. Why does this matter? If these peptides are ultimately added to the https://t.co/uMJHYVSvWl

Peptide News, last 24-72h: 1. FDA's PCAC hearing on 7 research peptides is next week (July 23-24) — the biggest thing in the space right now. The Pharmacy Compounding Advisory Committee meets at FDA White Oak to vote on whether BPC-157, TB-500, MOTS-c, KPV (day 1) and Semax,